deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT03899792

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors (LIBRETTO-121)

A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors

Sponsor: Eli Lilly and Company

Conditions Infantile Fibrosarcoma Infantile Myofibromatosis Medullary Thyroid Cancer Papillary Thyroid Cancer Soft Tissue Sarcoma
Interventions Selpercatinib
Updated 33 times since 2019 Last updated: Jan 2, 2026 Started: Jun 13, 2019 Primary completion: Nov 8, 2024 Completion: May 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03899792, this PHASE1/PHASE2 trial focuses on Infantile Fibrosarcoma and Infantile Myofibromatosis and remains ongoing. Sponsored by Eli Lilly and Company, it has been updated 33 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Apr 2022 · 3 months · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Mar 2023 · 4 months · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Aug 2023 · 3 months · monthly snapshot~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Feb 2024 · 3 months · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~May 2025 · 3 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 4 months · monthly snapshot

Change History

33 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Sep 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. May 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Feb 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Sep 2024 — Feb 2025 [monthly]

    Recruiting PHASE1/PHASE2

▶ Show 28 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  2. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  3. Mar 2024 — Apr 2024 [monthly]

    Recruiting PHASE1_PHASE2

  4. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE1_PHASE2

  5. Nov 2023 — Feb 2024 [monthly]

    Recruiting PHASE1_PHASE2

  6. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE1_PHASE2

  7. Aug 2023 — Oct 2023 [monthly]

    Recruiting PHASE1_PHASE2

  8. May 2023 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  9. Mar 2023 — May 2023 [monthly]

    Recruiting PHASE1_PHASE2

  10. Nov 2022 — Mar 2023 [monthly]

    Recruiting PHASE1_PHASE2

  11. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1_PHASE2

  12. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE1_PHASE2

  14. Apr 2022 — Jun 2022 [monthly]

    Recruiting PHASE1_PHASE2

  15. Jan 2022 — Apr 2022 [monthly]

    Recruiting PHASE1_PHASE2

  16. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE1_PHASE2

  17. Oct 2021 — Dec 2021 [monthly]

    Recruiting PHASE1_PHASE2

  18. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1_PHASE2

  19. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  20. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE1_PHASE2

  21. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE1_PHASE2

  22. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE1_PHASE2

  23. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1_PHASE2

  24. Nov 2019 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  25. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

  26. Aug 2019 — Oct 2019 [monthly]

    Recruiting PHASE1_PHASE2

  27. Jun 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  28. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
  • Loxo Oncology, Inc.
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Barcelona, Spain , Boston, United States , Chuo-ku, Japan , Cincinnati, United States , Copenhagen, Denmark , Dallas, United States , Heidelberg, Germany , Hiroshima, Japan , Houston, United States and 16 more locations